Nathaniel Simons
Meritage Group
Nathaniel Simons Valeant Pharmaceuticals International Inc stake
total: 301
Meritage Group VRX trades
- Total transactions:
- 10
- New positions:
- 1
- Sold out:
- 1
- Added:
- 5
- Reduced:
- 3
- Held since:
- 2013 Q2 or earlier
- Held for:
- 10+ quarters
- Latest activity:
- 2015 Q4
According to 2026 Q1 report, Nathaniel Simons doesn't hold any Valeant Pharmaceuticals International Inc (VRX) shares. Meritage Group has held VRX since at least 2013 Q2 with about 1.19M shares in our earliest available record. Since at least 2013 Q2, Meritage Group has made 9 more transactions.
When did Nathaniel Simons sell Valeant Pharmaceuticals International Inc (VRX)?
Nathaniel Simons sold off the entire Valeant Pharmaceuticals International Inc (VRX) position in 2015 Q4.
Estimated cost basis*
- Weighted AVG buy price:
- $110.33
- Weighted AVG sell price:
- $166.02
Nathaniel Simons's historical trades in Valeant Pharmaceuticals International Inc
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2015 Q4
|
0.00%
|
$178.38
|
-100% (-1,344,024)
|
|||
|
2015 Q3
|
6.33%
|
$178.38
|
+0.11% (+1,457)
|
|||
|
2015 Q2
|
6.99%
|
$222.15
|
-0.10% (-1,403)
|
|||
|
2015 Q1
|
7.21%
|
$198.62
|
+23.95% (+259,666)
|
|||
|
2014 Q4
|
4.23%
|
$143.11
|
-31.44% (-497,347)
|
|||
|
2014 Q3
|
5.65%
|
$131.20
|
+0.02% (+347)
|
|||
|
2014 Q2
|
5.60%
|
$126.12
|
+15.12% (+207,737)
|
|||
|
2014 Q1
|
5.10%
|
$131.83
|
-10.14% (-155,036)
|
|||
|
2013 Q4
|
5.61%
|
$117.40
|
+28.97% (+343,374)
|
|||
|
2013 Q2
|
3.46%
|
$86.08
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.